Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sung-Soo | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.date.available | 2020-02-27T05:40:48Z | - |
dc.date.created | 2020-02-05 | - |
dc.date.issued | 2019-01 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/2056 | - |
dc.description.abstract | Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56.3%. Three patients with creatinine clearance <30 ml/min even achieved an overall response. The median progression-free survival was 2.7 months with 28.9% (95% CI, 9.0-52.8) of 6-month progression-free survival. All infusion-related reactions, including >= Grade 3 back pain (6.3%) and dyspnea (6.3%), were manageable. The most common hematologic and non-hematological adverse events were anemia (62.5%) and upper respiratory infection (43.8%). >= Grade 3 bacterial infectious adverse events were identified, including upper and lower respiratory infection (12.5% and 18.8%) and death following sepsis (6.3%). We observed acceptable outcomes of daratumumab monotherapy on relapsed or refractory multiple myeloma patients including even a few subjects with high comorbidity, despite relatively frequent infectious adverse events. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.subject | IMPROVED SURVIVAL | - |
dc.subject | MANAGEMENT | - |
dc.subject | THERAPY | - |
dc.title | Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000465323500014 | - |
dc.identifier.doi | 10.1093/jjco/hyy177 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY, v.49, no.1, pp.92 - 95 | - |
dc.identifier.scopusid | 2-s2.0-85059502898 | - |
dc.citation.endPage | 95 | - |
dc.citation.startPage | 92 | - |
dc.citation.title | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 49 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | CD38 | - |
dc.subject.keywordAuthor | Daratumumab | - |
dc.subject.keywordAuthor | relapsed | - |
dc.subject.keywordAuthor | refractory | - |
dc.subject.keywordAuthor | multiple myeloma | - |
dc.subject.keywordPlus | IMPROVED SURVIVAL | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | THERAPY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.